Abstract
Invasive fungal infections are a serious threat to public health, particularly to people with compromised or suppressed immunity. Although the current antifungal therapies have been significantly improved, the outcome is still far from satisfactory, partly due to the limited number of classes of clinically available antifungals, the development of resistance to current antifungals, and the challenges of proper and early diagnosis. Recent advances in the development of new antifungals, although still in the investigational stages, offer some new hope of improving the future of antifungal therapy. Here, we review literature regarding the antifungal activities of several FDA-approved drugs, which were originally intended for treating other conditions, as well as newly discovered natural/artificial compounds. We focus on their mechanisms of action, limitations, and potential in treating fungal infections. The diverse mechanisms of action of these compounds summarized here can provide new directions for future endeavors on antifungal drug development.
Keywords: Polymyxin, tamoxifen, amiodarone, sertraline, occidiofungin, saponins, retigeric acid B, arylamidine derivative, drug synergy, compromised or suppressed immunity, antifungals, antifungal therapy, amphotericin B, azole therapy
Current Pharmaceutical Biotechnology
Title: Recent Progress on Antifungal Drug Development
Volume: 12 Issue: 8
Author(s): Bing Zhai and Xiaorong Lin
Affiliation:
Keywords: Polymyxin, tamoxifen, amiodarone, sertraline, occidiofungin, saponins, retigeric acid B, arylamidine derivative, drug synergy, compromised or suppressed immunity, antifungals, antifungal therapy, amphotericin B, azole therapy
Abstract: Invasive fungal infections are a serious threat to public health, particularly to people with compromised or suppressed immunity. Although the current antifungal therapies have been significantly improved, the outcome is still far from satisfactory, partly due to the limited number of classes of clinically available antifungals, the development of resistance to current antifungals, and the challenges of proper and early diagnosis. Recent advances in the development of new antifungals, although still in the investigational stages, offer some new hope of improving the future of antifungal therapy. Here, we review literature regarding the antifungal activities of several FDA-approved drugs, which were originally intended for treating other conditions, as well as newly discovered natural/artificial compounds. We focus on their mechanisms of action, limitations, and potential in treating fungal infections. The diverse mechanisms of action of these compounds summarized here can provide new directions for future endeavors on antifungal drug development.
Export Options
About this article
Cite this article as:
Zhai Bing and Lin Xiaorong, Recent Progress on Antifungal Drug Development, Current Pharmaceutical Biotechnology 2011; 12 (8) . https://dx.doi.org/10.2174/138920111796117292
DOI https://dx.doi.org/10.2174/138920111796117292 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems
Current Gene Therapy Natural Products and Cancer Stem Cells
Current Pharmaceutical Design Meet Our Editorial Board Member
Clinical Cancer Drugs Synthesis of (R)-2-benzylmorpholine employing catalytic stereospecific rearrangement of L-Phenylalaninol
Letters in Organic Chemistry Nerve Growth Factor: Early Studies and Recent Clinical Trials
Current Neuropharmacology Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors
Recent Patents on Anti-Cancer Drug Discovery Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Recent Developments in Patented DC-Based Immunotherapy for Various Malignancies
Recent Patents on Regenerative Medicine Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery The Use of Immortalized Cell Lines in GPCR Screening: The Good, Bad and Ugly.
Combinatorial Chemistry & High Throughput Screening Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Late Effects in Survivors of Childhood CNS Tumors: Review of Results From the Two Largest Survivorship Cooperative Groups
Current Cancer Therapy Reviews Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy Endogenous Regulators of Adult CNS Neurogenesis
Current Pharmaceutical Design Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
Current Drug Metabolism